Adjunctive raloxifene treatment improves attention and memory in men and women with schizophrenia

Molecular Psychiatry

Volumn 20, Issue 6, 2015, Pages 685-694

  Weickert, T W ^a,b,c   Weinberg, D ^a   Lenroot, R ^a,b,c   Catts, S V ^b,d   Wells, R ^a,b   Vercammen, A ^a,b,c,e   O'Donnell, M ^a   Galletly, C ^f,g   Liu, D ^f,g   Balzan, R ^f,h   Short, B ^b   Pellen, D ^b   Curtis, J ^a   Carr, V J ^a,c   Kulkarni, J ⁱ   Schofield, P R ^a,b,c   Weickert, C S ^a,b,c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

^c SCHIZOPHRENIA RESEARCH INSTITUTE   (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e AUSTRALIAN CATHOLIC UNIVERSITY   (Australia)

^f UNIVERSITY OF ADELAIDE   (Australia)

^g Central Adelaide Local Health Network   (Australia)

^h FLINDERS UNIVERSITY   (Australia)

ⁱ Australia   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RALOXIFENE; ANTIESTROGEN;

ABDOMINAL PAIN; ADJUVANT THERAPY; ADULT; ARTICLE; ATTENTION; CLINICAL ARTICLE; COMMON COLD; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DEPRESSION ANXIETY STRESS SCALE; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DYSPEPSIA; EMOTIONAL DISORDER; FEMALE; HALLUCINATION; HEADACHE; HORMONE DETERMINATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LANGUAGE; LETHARGY; MALE; METABOLIC DISORDER; MUSCLE CRAMP; NAUSEA; NUTRITIONAL DISORDER; PANIC; PARANOIA; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOLOGIC TEST; RANDOMIZED CONTROLLED TRIAL; SATISFACTION WITH LIFE SCALE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SHORT FORM 36; SIDE EFFECT; SLEEP DISORDER; STRUCTURED CLINICAL INTERVIEW FOR DSM DISORDERS; VERBAL MEMORY; WECHSLER INTELLIGENCE SCALE; WECHSLER MEMORY SCALE; WECHSLER TEST OF ADULT READING; WEIGHT GAIN; WORKING MEMORY; ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; AUSTRALIA; BLOOD; CLINICAL TRIAL; COMPLICATION; LONGITUDINAL STUDY; MEMORY DISORDERS; MIDDLE AGED; MULTICENTER STUDY; NEUROPSYCHOLOGICAL TEST; NONPARAMETRIC TEST; PATIENT COMPLIANCE; PSYCHOLOGICAL RATING SCALE; SEXUAL DEVELOPMENT; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; AUSTRALIA; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MEMORY DISORDERS; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PATIENT COMPLIANCE; PSYCHIATRIC STATUS RATING SCALES; RALOXIFENE HYDROCHLORIDE; SCHIZOPHRENIA; SEX CHARACTERISTICS; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84925428575     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2015.11     Document Type: Article

References (75)

1. Levine SZ, Rabinowitz J, Ascher-Svanum H, Faries DE, Lawson AH. Extent of attaining and maintaining symptom remission by antipsychotic medication in the treatment of chronic schizophrenia: Evidence from the CATIE study. Schizophr Res 2011; 133: 42-46.
2. Weickert TW, Goldberg TE. The course of cognitive impairment in patients with schizophrenia. In: Sharma T, Harvey P (eds). Cognition in Schizophrenia: Impairments, importance and treatment strategies. Oxford University Press: New York, NY, 2000; 3-15.
3. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996; 153: 321-330.
4. Hyman SE. Revitalizing psychiatric therapeutics. Neuropsychopharmacology 2014; 39: 220-229.
5. Burke KC, Burke JD Jr, Regier DA, Rae DS. Age at onset of selected mental disorders in five community populations. Arch Gen Psychiatry 1990; 47: 511-518.
6. Allen KM, Fung SJ, Rothmond DA, Noble PL, Weickert CS. Gonadectomy increases neurogenesis in the male adolescent rhesus macaque hippocampus. Hippocampus 2014; 24: 225-238.
7. Morris RW, Fung SJ, Rothmond DA, Richards B, Ward S, Noble PL et al. The effect of gonadectomy on prepulse inhibition and fear-potentiated startle in adolescent rhesus macaques. Psychoneuroendocrinology 2010; 35: 896-905.
8. Richards AB, Morris RW, Ward S, Schmitz S, Rothmond DA, Noble PL et al. Gonadectomy negatively impacts social behavior of adolescent male primates. Horm Behav 2009; 56: 140-148.
9. Hafner H. Gender differences in schizophrenia. Psychoneuroendocrinology 2003; 28: 17-54.
10. Gur RE, Petty RG, Turetsky BI, Gur RC. Schizophrenia throughout life: sex differences in severity and profile of symptoms. Schizophr Res 1996; 21: 1-12.
11. Goldstein JM, Link BG. Gender and the expression of schizophrenia. J Psychiatr Res 1988; 22: 141-155.
12. Hafner H, Maurer K, Loffler W, Riecher-R A. The influence of age and sex on the onset and early course of schizophrenia. Br J Psychiatry 1993; 162: 80-86.
13. Gattaz WF, Vogel P, Riecher-Rossler A, Soddu G. Influence of the menstrual cycle phase on the therapeutic response in schizophrenia. Biol Psychiatry 1994; 36: 137-139.
14. Hallonquist JD, Seeman MV, Lang M, Rector NA. Variation in symptom severity over the menstrual cycle of schizophrenics. Biol Psychiatry 1993; 33: 207-209.
15. Riecher-Rössler A, Häfner H, Stumbaum M, Maurer K, Schmidt R. Can estradiol modulate schizophrenic symptomatology? Schizophr Bull 1994; 20: 203-214.
16. McNeil TF, Kaij L, Maimquist Larsson A. Women with nonorganic psychosis: pregnancy's effect on mental health during pregnancy. Acta Psychiatr Scand 1984; 70: 140-148.
17. Akhondzadeh S, Rezaei F, Larijani B, Nejatisafa A-A, Kashani L, Abbasi SH. Correlation between testosterone, gonadotropins and prolactin and severity of negative symptoms in male patients with chronic schizophrenia. Schizophr Res 2006; 84: 405-410.
18. Vercammen A, Skilleter AJ, Lenroot R, Catts SV, Weickert CS, Weickert TW. Testosterone is inversely related to brain activity during emotional inhibition in schizophrenia. PLoS One 2013; 8: E77496.
19. Moore L, Kyaw M, Vercammen A, Lenroot R, Kulkarni J, Curtis J et al. Serum testosterone levels are related to cognitive function in men with schizophrenia. Psychoneuroendocrinology 2013; 38: 1717-1728.
20. Sherwin BB. Estrogen and cognitive functioning in women. Endocr Rev 2003; 24: 133-151.
21. Hao J, Rapp PR, Janssen WGM, Lou W, Lasley BL, Hof PR et al. Interactive effects of age and estrogen on cognition and pyramidal neurons in monkey prefrontal cortex. Proc Natl Acad Sci 2007; 104: 11465-11470.
22. Woolley CS, McEwen BS. Estradiol regulates hippocampal dendritic spine density via an N-methyl-D-aspartate receptor-dependent mechanism. J Neurosci 1994; 14: 7680-7687.
23. Wang J, Cheng CM, Zhou J, Smith A, Weickert CS, Perlman WR et al. Estradiol alters transcription factor gene expression in primate prefrontal cortex. J Neurosci Res 2004; 76: 306-314.
24. Perlman WR, Tomaskovic-Crook E, Montague DM, Webster MJ, Rubinow DR, Kleinman JE et al. Alteration in estrogen receptor alpha mRNA levels in frontal cortex and hippocampus of patients with major mental illness. Biol Psychiatry 2005; 58: 812-824.
25. Montague D, Weickert CS, Tomaskovic-Crook E, Rothmond DA, Kleinman JE, Rubinow DR. Oestrogen receptor alpha localisation in the prefrontal cortex of three mammalian species. J Neuroendocrinol 2008; 20: 893-903.
26. Perlman WR, Matsumoto M, Beltaifa S, Hyde TM, Saunders RC, Webster MJ et al. Expression of estrogen receptor alpha exon-deleted mRNA variants in the human and non-human primate frontal cortex. Neuroscience 2005; 134: 81-95.
27. Weickert CS, Miranda-Angulo AL, Wong J, Perlman WR, Ward SE, Radhakrishna V et al. Variants in the estrogen receptor alpha gene and its mRNA contribute to risk for schizophrenia. Hum Mol Genet2008; 17: 2293-2309.
28. Wong J, Weickert CS. Transcriptional interaction of an estrogen receptor splice variant and ErbB4 suggests convergence in gene susceptibility pathways in schizophrenia. J Biol Chem 2009; 284: 18824-18832.
29. LeBlanc ES, Janowsky J, Chan BKS, Nelson HD. Hormone replacement therapy and cognition: systematic review and meta-analysis. JAMA 2001; 285: 1489-1499.
30. Good KP, Kopala LC, Martzke JS, Fluker M, Seeman MV, Parish B et al. Hormone replacement therapy in postmenopausal women with schizophrenia: preliminary findings. Schizophr Res 1999.
31. Kulkarni J, Gavrilidis E, Wang W, Worsley R, Fitzgerald PB, Gurvich C et al. Estradiol for treatment-resistant schizophrenia: a large-scale randomized-controlled trial in women of child-bearing age. Mol Psychiatry 2014.
32. Ko Y-H, Joe S-H, Cho W, Park J-H, Lee J-J, Jung I-K et al. Effect of hormone replacement therapy on cognitive function in women with chronic schizophrenia. Int J Psychiatry Clin Pract 2006; 10: 97-104.
33. Begemann MJH, Dekker CF, van Lunenburg M, Sommer IE. Estrogen augmentation in schizophrenia: a quantitative review of current evidence. Schizophr Res 2012; 141: 179-184.
34. Kulkarni J, de Castella A, Smith D, Taffe J, Keks N, Copolov D. A clinical trial of the effects of estrogen in acutely psychotic women. Schizophr Res 1996; 20: 247-252.
35. Kulkarni J, de Castella A, Headey B, Marston N, Sinclair K, Lee S et al. Estrogens and men with schizophrenia: is there a case for adjunctive therapy? Schizophr Res 2011; 125: 278-283.
36. Kulkarni J, de Castella A, Fitzgerald PB, Gurvich CT, Bailey M, Bartholomeusz C et al. Estrogen in severe mental illness: a potential new treatment approach. Arch Gen Psychiatry 2008; 65: 955-960.
37. Barrett-Connor E, Stuenkel CA. Hormone replacement therapy (HRT)-risks and benefits. Int J Epidemiol 2001; 30: 423-426.
38. Landry M, Lévesque D, Di Paolo T, Eacute R, Egrave S. Estrogenic properties of raloxifene, but not tamoxifen, on D2 and D3 dopamine receptors in the rat forebrain. Neuroendocrinology 2002; 76: 214-222.
39. Khan MM, Wakade C, de Sevilla L, Brann DW. Selective estrogen receptor modulators (SERMs) enhance neurogenesis and spine density following focal cerebral ischemia. J Steroid Biochem Mol Biol 2014; 146: 38-47.
40. González-Burgos I, Rivera-Cervantes MC, Velázquez-Zamora DA, Feria-Velasco A, Garcia-Segura LM. Selective estrogen receptor modulators regulate dendritic spine plasticity in the hippocampus of male rats. Neural Plast 2011; 2012: 309494.
41. Goekoop R, Duschek EJ, Knol DL, Barkhof F, Netelenbos C, Scheltens P et al. Raloxifene exposure enhances brain activation during memory performance in healthy elderly males; its possible relevance to behavior. NeuroImage 2005; 25: 63-75.
42. Nickelsen T, G Lufkin E, Lawrence Riggs B, A Cox D, H Crook T. Raloxifene hydrochloride, a selective estrogen receptor modulator: safety assessment of effects on cognitive function and mood in postmenopausal women. Psychoneuroendocrinology 1999; 24: 115-128.
43. Usall J, Huerta-Ramos E, Iniesta R, Cobo J, Araya S, Roca M et al. Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a doubleblind, randomized, placebo-controlled trial. J Clin Psychiatry 2011; 72: 1552.
44. Wong J, Seeman MV, Shapiro H. Case report: raloxifene in postmenopausal women with psychosis: preliminary findings. Am J Geriatric Psychiatry 2003; 11: 697-698.
45. Kulkarni J, Gurvich C, Lee SJ, Gilbert H, Gavrilidis E, de Castella A et al. Piloting the effective therapeutic dose of adjunctive selective estrogen receptor modulator treatment in postmenopausal women with schizophrenia. Psychoneuroendocrinology 2010; 35: 1142-1147.
46. Huerta-Ramos E, Iniesta R, Ochoa S, Cobo J, Miquel E, Roca M et al. Effects of raloxifene on cognition in postmenopausal women with schizophrenia: a doubleblind, randomized, placebo-controlled trial. Eur Neuropsychopharmacol 2014; 24: 223-231.
47. First MB. Structured clinical interview for DSM-IV-TR axis I disorders: SCID-I: biometrics research department. New York State Psychiatric Institutute 2007.
48. Raloxifene: Highlights of Prescribing Information: Eli Lilly and Company. 2011. Available at http://pi. lilly. com/us/evista-pi. pdf.
49. Wechsler D. Wechsler Adult Intelligence Scale. 3rd edn Pyschological Corporation: San Antonio, TX, USA: 2001.
50. Wechsler D. Wechsler Test of Adult Reading. The Psychological Corporation: San Antonio, TX, USA 2001.
51. Lezak M. Neuropsychological Assessment. 4th edn Oxford University Press: New York, NY: 2004.
52. Reitan RWD. The Halstead-Reitan Neuropsychological Test Battery: Therapy and Clinical Interpretation. Neuropsychological Press: Tucson, AZ, USA: 1985.
53. Wechsler D. Wechsler Memory Scale-Revised. The Psychological Corporation: San Antonio, TX, USA, 1987.
54. Kay SR, Flszbein A, Opfer LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261.
55. Lovibond S, Lovibond P. Manual for the Depression Anxiety Stress Scale. 2nd edn Psychology Foundation: Sydney, Australia: 1995.
56. Ware JE, Kosinski M, Dewey JE, Gandek B. SF-36 health survey: manual and interpretation guide: Quality Metric Inc. 2000.
57. Wilkinson G, Hesdon B, Wild D, Cookson R, Farina C, Sharma V et al. Self-report quality of life measure for people with schizophrenia: the SQLS. Br J Psychiatry 2000; 177: 42-46.
58. Woods JR, Williams JG, Tavel M. The two-period crossover design in medical research. Ann Int Med 1989; 110: 560-566.
59. Jacobson NS, Truax P. Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol 1991; 59: 12.
60. Williams LM, Simms E, Clark CR, Paul RH, Rowe D, Gordon E. The test-retest reliability of a standardized neurocognitive and neurophysiological test battery:"neuromarker". Int J Neurosci 2005; 115: 1605-1630.
61. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789.
62. Buchanan RW, Davis M, Goff D, Green MF, Keefe RSE, Leon AC et al. A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr Bull 2005; 31: 5-19.
63. McGurk SR, Meltzer HY. The role of cognition in vocational functioning in schizophrenia. Schizophr Res 2000; 45: 175-184.
64. Keefe RSE, Buchanan RW, Marder SR, Schooler NR, Dugar A, Zivkov M et al. Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? Schizophr Bull 2013; 39: 417-435.
65. Levkovitz Y, Mendlovich S, Riwkes S, Braw Y, Levkovitch-Verbin H, Gal G et al. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry 2010; 71: 138.
66. Buchanan R, Conley R, Dickinson D, Ball M, Feldman S, Gold J et al. Galantamine for the treatment of cognitive impairments in people with schizophrenia. Am J Psychiatry 2008; 165: 82-89.
67. Eng-Wong J, Reynolds JC, Venzon D, Liewehr D, Gantz S, Danforth D et al. Effect of raloxifene on bone mineral density in premenopausal women at increased risk of breast cancer. J Clin Endocrinol Metab 2006; 91: 3941-3946.
68. Uebelhart B, Herrmann F, Pavo I, Draper MW, Rizzoli R. Raloxifene treatment is associated with increased serum estradiol and decreased bone remodeling in healthy middle aged men with low sex hormone levels. J Bone Miner Res 2004; 19: 1518-1524.
69. Boss L, Kang D-H, Marcus M, Bergstrom N. Endogenous sex hormones and cognitive function in older adults a systematic review. West J Nurs Res 2014; 36: 388-426.
70. Salminen EK, Portin RI, Koskinen AI, Helenius HYM, Nurmi MJ. Estradiol and cognition during androgen deprivation in men with prostate carcinoma. Cancer 2005; 103: 1381-1387.
71. Zakzanis KK, Mraz R, Graham SJ. An fMRI study of the Trail Making Test. Neuropsychologia 2005; 43: 1878-1886.
72. Sass KJ, Sass A, Westerveld M, Lencz T, Novelly RA, Kim JH et al. Specificity in the correlation of verbal memory and hippocampal neuron loss: dissociation of memory, language, and verbal intellectual ability. J Clin Exp Neuropsychol 1992; 14: 662-672.
73. Sherwin BB, Chertkow H, Schipper H, Nasreddine Z. A randomized controlled trial of estrogen treatment in men with mild cognitive impairment. Neurobiol Aging 2011; 32: 1808-1817.
74. Yonker JE, Adolfsson R, Eriksson E, Hellstrand M, Nilsson L-G, Herlitz A. Verified hormone therapy improves episodic memory performance in healthy postmenopausal women. Aging Neuropsychol Cogn 2006; 13: 291-307.
75. Barry D, Bates ME, Labouvie E. FAS and CFL forms of verbal fluency differ in difficulty: a meta-analytic study. Appl Neuropsychol 2008; 15: 97-106.